Acro Biomedical Co., Ltd.
ACBM · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $1 | $1 |
| % Growth | – | -100% | -45% | – |
| Cost of Goods Sold | $0 | $0 | $1 | $1 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | 21.3% | 21.7% |
| R&D Expenses | $0 | $5 | $10 | $5 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $4 | $6 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $9 | $16 | $8 |
| Operating Income | -$0 | -$9 | -$16 | -$8 |
| % Margin | – | – | -2,410% | -642.5% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | -$9 | -$16 | -$8 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$9 | -$16 | -$8 |
| % Margin | – | – | -2,410.2% | -643.2% |
| EPS | -0.001 | -0.15 | -0.26 | -0.14 |
| % Growth | 99.5% | 42.3% | -85.7% | – |
| EPS Diluted | -0.001 | -0.15 | -0.26 | -0.14 |
| Weighted Avg Shares Out | 60 | 60 | 60 | 54 |
| Weighted Avg Shares Out Dil | 60 | 60 | 60 | 54 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $9 | $0 | $8 |
| EBITDA | -$0 | $0 | -$16 | $0 |
| % Margin | – | – | -2,410% | 0% |